Jagsonpal Pharma announces ₹40 Cr buyback offer at ₹250 per share
Jagsonpal Pharmaceuticals Limited is launching a buyback of up to 16 lakh equity shares at ₹250 per share, totaling ₹40 crore. The buyback period runs from May 8 to May 14, 2026. This offer represents 2.38% of the company's total equity share capital.
A ₹40 crore buyback is a significant but not overwhelmingly large amount for a publicly traded company, indicating a moderate impact on the company's financials and share structure.
The buyback announcement is generally positive for shareholders as it provides an opportunity to sell shares at a premium and can signal management's confidence in the company's valuation.
Jagsonpal Pharmaceuticals Limited has announced a buyback offer for up to 16,00,000 fully paid-up equity shares, representing 2.38% of its total equity share capital. The buyback will be conducted through the "Tender Offer" route at a price of ₹250 per equity share, aggregating up to ₹40,00,00,000 (Rupees Forty Crores only), excluding transaction costs.
The record date for determining eligible shareholders was Monday, May 04, 2026. The buyback opened on Friday, May 08, 2026, and will close on Thursday, May 14, 2026. The last date for receipt of completed tender forms and other specified documents by the Registrar to the Buyback is also Thursday, May 14, 2026, by 5:00 PM IST. The settlement of bids by the Clearing Corporation/BSE is scheduled for Thursday, May 21, 2026.
This buyback is undertaken in accordance with the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, and other applicable provisions of the Companies Act, 2013. The buyback offer size represents 18.35% of the company's aggregate paid-up equity share capital and free reserves as per the latest financial statements for the fiscal year ended March 31, 2025, which is within the statutory limit of 25%. The Letter of Offer has been dispatched to eligible shareholders via electronic means.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under buyback announcement. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.